Ethyl apovincaminate in the treatment of sensorineural impairment of hearing.
Ethyl apovincaminate (EGH-4405, Cavinton) treatment has been used in various sensorineural impairments of hearing as well as in ear diseases associated with vertigo. As shown by experinces, presbyacusis, vascular impairment of hearing and in certain cases toxic hypacusia are improved by Cavinton. Besides audiometric improvement of pure tone, significant improvement was noted in the speech-audiogram in all three groups of disease. Certain affections of the ear accompanied by vertigo responded to Cavinton. In Menière's disease it has proved to be superior to the vasodilators used up to now.
D003638:Deafness / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D007759:Labyrinth Diseases / Q000188:drug therapy; D011304:Presbycusis / Q000188:drug therapy; D014665:Vasodilator Agents; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014748:Vinca Alkaloids